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Dear Prof. Ahluwalia,
we are submitting a manuscript entitled “Fenretinide treatment accelerates 
atherosclerosis development in apoE-deficient mice in spite of beneficial metabolic effects“ 
by Busnelli et al., to be considered for publication in British Journal of Pharmacology.
Fenretinide, a synthetic retinoid derivative, is known for a much lower toxicity with respect 
to other retinoids, and is currently employed in several preclinical and clinical trials testing 
its ability to inhibit and treat different forms of cancer. In addition to this seemingly 
protective action, a plethora of beneficial metabolic effects have been described in the 
literature in both experimental models and patients, including an ameliorated glucose 
tolerance, lowered plasma lipid levels and a reduced fat mass deposition. All these 
evidences spurred us to investigate whether these beneficial effects would translate into a 
reduced atherosclerosis development in an animal model widely employed in this regard, 
the apolipoprotein E knockout mouse.
As yet untested, we could confirm that all evidences pointing towards beneficial metabolic 
effects were indeed confirmed also in this model: we found that fenretinide lowered the fat 
mass accumulation upon high-fat diet feeding, resulted into a lower basal glycemia and 
was able to reduce total cholesterol, phospholipids and triglycerides especially.
Very surprisingly, we found that atherosclerosis was indeed increased, and by a significant 
margin, in the treated group. With the aim of pinpoint the mechanism responsible for this 
result, we set out to deeply characterize our model, and we found how fenretinide exerts 
detrimental effects on erythrocytes as well as monocytes and leukocytes, effects partly  
stemming from an impaired myelopoiesis and erythropoiesis. To rule out possible model 
biases, we enrolled wild-type mice that were likewise treated. While it is not possible to 
evaluate atherosclerosis in such a model, we were able to identify the vast majority of 
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fenretinide treatment detrimental effects also in wild-type mice (enlarged spleen, 
leucocytosis). As already considered, Fenretinide is now being used to treat problematic 
patients with life-threatening conditions, and the adverse effects that we regard as 
detrimental are a minor concern in this kind of studies. However, our study raises a red 
flag, should fenretinide be repurposed as a treatment for more ordinary ailments, and/or 
for chronic treatments.
In summary, despite the beneficial metabolic effects that fenretinide reportedly exerts and 
that we confirmed, we demonstrate how fenretinide can negatively impact atherosclerosis 
development, and particular care must be taken should fenretinide enter everyday clinical 
practice.
We hope that this work will be considered of interest to the readers of British Journal of 
Pharmacology.
Sincerely yours, 
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Abbreviations
apoE Apolipoprotein E
Ctrl Control, control group
EKO apoE knockout
Fen Fenretinide, fenretinide-treated group
HCT Hematocrit
HGB Hemoglobin concentration
MCH Mean corpuscular hemoglobin
MCHC Mean corpuscular hemoglobin concentration
MCV Mean corpuscular volume
MP Monocyte progenitors
PL Phospholipids
PLT Platelet
RBC Red blood cells
TC Total cholesterol
TG Triglycerides
WAT White adipose tissue
WBC Total leukocytes, white blood cells
WT Wild-type
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Abstract
Background and Purpose: Fenretinide, a synthetic retinoid derivative first 
investigated for cancer prevention and treatment, has been shown to ameliorate 
glucose tolerance and the plasma lipid profile, and to reduce body fat mass. These 
effects, together with its ability to inhibit ceramide synthesis, have suggested that 
fenretinide may display anti-atherosclerotic effects. 
Experimental Approach: To this aim, 9-weeks-old apoE-knockout (EKO) female 
mice were fed for 12 weeks a Western diet, without (Control) or with (0.1% w/w) 
fenretinide. As a reference, wild-type (WT) mice were likewise treated. Growth and 
metabolic parameters were monitored throughout the study. Atherosclerosis 
development was evaluated in the aorta and at the aortic sinus. Blood and lymphoid 
organs were further characterized with thorough cytological/histological and 
immunocytofluorimetric analyses. 
Key Results: Fenretinide treatment significantly lowered body weight, glucose levels 
and plasma levels of total cholesterol, triglycerides and phospholipids. In the liver, 
fenretinide remarkably reduced hepatic glycogenosis and steatosis driven by the 
Western diet. Treated spleens were abnormally enlarged, with severe follicular 
atrophy and massive extramedullary hematopoiesis. Severe renal hemosiderin 
deposition was observed in treated EKO. Treatment resulted in a threefold increase of 
total leukocytes (WT and EKO) and raised the activated/resting monocyte ratio in 
EKO. Finally, atherosclerosis development was markedly increased at the aortic arch 
(34.4±7.3% vs 26.1±5.8%, +32%), thoracic (14.3±4.9% vs 4.9±2.1%, +191%) and 
abdominal aorta (7.6±3.3% vs 3.3±1.8%, +130%) of fenretinide-treated mice.
Conclusions and Implications: We provide the first evidence that, despite beneficial 
metabolic effects, fenretinide treatment may prove detrimental for atherosclerosis 
development.
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1. Introduction
Fenretinide is a derivative of retinoic acid, widely investigated as chemopreventive 
option in different forms of cancer and as chemotherapeutic agent in both pediatric 
and adult malignancies (Cooper et al., 2017). Whereas retinoic acid and other related 
compounds preferentially accumulate in the liver, causing hepatic toxicity with 
prolonged exposure, fenretinide, together with its metabolites, is preferentially stored 
in fatty tissues, providing a safer profile to this molecule (Mody and Mcilroy, 2014). 
The retinoid metabolism pathway is known to play an important role in body mass 
regulation and adipocyte biology (Zizola et al., 2010; Berry et al., 2012) and all-trans-
retinoic acid, the most active metabolite of retinol, has been shown to positively affect 
obesity and glucose h meostasis (Berry and Noy, 2009). Fenretinide improves 
glucose response and modulates body fat mass, at least in part through modulation of 
retinoid homeostasis genes (Mcilroy et al., 2013; Mody and Mcilroy, 2014). 
Additionally, fenretinide prevents ceramide accumulation by inhibiting 
dihydroceramide desaturase, which catalyzes the final step of de novo ceramide 
synthesis (Bikman et al., 2012). Given the emerging role of ceramides in promoting 
insulin resistance and other obesity-induced metabolic alterations (Aburasayn et al., 
2016; Petersen and Shulman, 2018), this m chanism may certainly account for the 
favourable metabolic effects of fenretinide treatment (Bikman et al., 2012; Mody and 
Mcilroy, 2014). Further, fenretinide administration to high fat fed mice has been 
shown to significantly reduce hepatic steatosis (Preitner et al., 2009; Koh et al., 2012) 
and to moderately lower plasma lipids, possibly by increasing liver fatty acid 
oxidation  (Koh et al., 2012).
All these favourable metabolic effects exerted by fenretinide suggest that this drug 
may be protective against cardiovascular disease. In the present study, fenretinide was 
administered to apolipoprotein E (apoE)-deficient mice to investigate a possible 
beneficial effect of this drug on atherosclerosis development. Although fenretinide 
treatment favourably affected glucose and lipid metabolism, it unexpectedly worsened 
atherosclerosis, possibly through a dramatic increase of the immune/inflammatory 
response.
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2. Methods
2.1. Animals, diet and pharmacological treatment. Procedures involving animals 
and their care were conducted in accordance with institutional guidelines that are in 
compliance with national (D.L. No. 26, March 4, 2014, G.U. No. 61 March 14, 2014) 
and international laws and policies (EEC Council Directive 2010/63, September 22, 
2010: Guide for the Care and Use of Laboratory Animals, United States National 
Research Council, 2011). The experimental protocol was approved by the Italian 
Ministry of Health (Protocollo 428/2015-PR).
Fifty apoE knockout female mice (strain 002052), and twenty C57BL/6 wild type 
(strain 027) aged 8 weeks, were purchased from Charles River Laboratories (Calco, 
Italy) and housed at constant temperature and relative humidity. Scobis Uno, a 
vegetable bedding made of wood particles obtained from spruce, was used. After one 
week of acclimatization, mice were fed for 12 weeks a high-fat diet (adjusted calories 
42% from fat, 0.2% cholesterol) without supplementation (Control), or supplemented 
with Fenretinide 0.1% w/w. Mice were house 3-4 per cage.
2.2. Blood and tissue harvesting. At the end of the dietary treatment, mice were 
anesthetized with 2% isoflurane (Parolini et al., 2014), and blood was collected from 
a subset of mice, after 5 hours fast, for plasma lipid quantification, as described 
(Busnelli et al., 2017). In a second subset of unfasted mice, blood was collected for 
FACS (0.1% w/v EDTA) from the retroorbital plexus. For haematological analyses, 
blood was collected through cardiac puncture in 3.8% Na-citrate as described 
(Amadio et al., 2017a).
Blood was then removed by perfusion with PBS, and aorta was rapidly harvested as 
described (Parolini et al., 2017), longitudinally opened, pinned flat on a black wax 
surface in ice-cold PBS and photographed unstained for plaque quantification (see 
below). 
Heart, liver, lungs, abdominal white adipose tissue (WAT), kidneys, skin, spleen and 
bone marrow were harvested. Liver and WAT were snap-frozen in liquid nitrogen for 
subsequent molecular analyses. All listed tissues were processed for subsequent 
histological or cytological analyses. 
2.3. Plasma measurements and glucose tolerance test. 
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Plasma total cholesterol (TC), triglycerides (TG) and phospholipids (PL) were 
measured with enzymatic methods and lipid distribution among lipoproteins was 
analysed by FPLC (Marchesi et al., 2011).
For the glucose tolerance test, after 10 weeks of treatment mice were fasted for 5 
hours and then injected with 2 g/Kg glucose via i.p. injection of 20% w/v sterile 
glucose solution in PBS. Glucose levels were determined as described previously 
(Lachance et al., 2013).
2.4 Functional Fibrinogen – Plasma fibrinogen was assayed by Clauss method 
according to manufacturer’s instructions, as previously described (Amadio et al., 
2017b). Briefly, plasma samples were diluted 1:10 in imidazole buffer (Imidazole 
0.34%, NaCl 0.6%, Sodium citrate 0.15%, HCl 0.14%, Sodium azide 0.33%; pH 7.4). 
Two-hundred µL of each diluted plasma sample were pre-warmed at 37°C for 4 
minutes and then clot formation was promoted by the addition of 100 µL of liquid 
stable thrombin reagent (100 U/ml). The time taken for the clot to form is directly 
proportional to fibrinogen concentration present in the samples analyzed (Mackie et 
al., 2003).
2.5 Blood and bone marrow cytology.
2.5.1 Sampling. At sacrifice, blood was collected from the heart and immediately 
placed in 0.5 mL tubes containing EDTA, filled at their maximum capacity. 
Anticoagulated blood was stored at room temperature and transported to the 
laboratory to be processed within 4 hours from sampling as described below. 
Bone marrow was collected from the femur using a 24G syringe needle through the 
needle capillary technique: the femur was removed at necropsy and longitudinally 
split using a bone cutter and the needle was inserted in the bone marrow cavity. Once 
removed, the content of the needle was sprayed on a glass slide using a 1 mL syringe 
and the needle itself was rolled on the slide to smear either the material contained in 
the needle or the small drops of tissues remained in the outer surface of the needle. 
2.5.2 Hematology and Bone Marrow cytology. Routine hematology was performed on 
whole blood collected in EDTA using a laser-based cell counter (Sysmex XT-2000iV) 
validated in mice (Mathers et al., 2008). Samples with evident clots were excluded 
from the haematological analysis. The following parameters were evaluated: 
erythrocyte number (RBC), hemoglobin concentration (HGB), hematocrit (HCT), 
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mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), mean 
corpuscular hemoglobin concentration (MCHC), platelet number (PLT), number of 
total leukocytes (WBC), and of the different leukocyte populations: neutrophils, 
lymphocytes, monocytes, eosinophils, and basophils. The differential leucocyte 
counts provided by the instrument were verified through microscopic evaluation on 
May Grünwald Giemsa stained smears. During microscopic evaluation, particular 
attention was paid to the differentiation of mature (segmented) neutrophils and 
immature (band) neutrophils and to any possible morphological abnormality of 
erythrocytes, leukocytes and platelets. 
Bone marrow smears were stained with May Grünwald Giemsa and a 500 nucleated-
cell count was microscopically performed. The following parameters were recorded: 
myeloid:erythroid (M:E); number of cells belonging to the proliferative (P) pool 
(composed by blasts able to divide) or to the maturation (M) pool, in order to 
calculate, for each cell population, the P:M ratio and the percentage of precursors on 
the total number of cells belonging to each cell lineage (%EP = percentage of 
erythroid precursors and %MP = p rcentage of myeloid precursors); percentage of 
lymphocytes (%L) and plasma cells (%PL) on the total number of counted cells. Any 
possible abnormal morphology of cells of both proliferative and maturation pool was 
also recorded.
2.6. FACS Analyses.
2.6.1 Flow cytometry. All fluorochrome-conjugated antibodies were used at 1:100 
dilutions unless otherwise specified. Samples were acquired with Novocyte 3000 
(ACEA Biosciences) and analysed with Novoexpress software.
2.6.2 Blood immunophenotyping. 50 µL of blood were stained with the mix of 
fluorochrome-conjugated antibodies prepared in PBS containing, 2% FBS and 2µM 
EDTA (MACS buffer) at RT for 30 minutes in the dark. Following staining, red blood 
cells were lysed and fixed for 20 minutes at RT, washed twice and resuspended with 
MACS buffer and analysed immediately.
2.6.3. Spleen and bone marrow cells immunophenotyping. Spleens were weighed, 
then immune cells were isolated. A uniform cell suspension was prepared by the 
spleens through a 70 µm cell strainer; after red blood cell lysis (Red Cell Blood Lysis 
Buffer), cells were spun down at 600×g for 5 minutes suspended in MACS buffer for 
cell counting.
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Bone marrow cells were isolated by flushing femurs with MACS buffer. Cells were 
then dispersed with a 5 mL syringe and pass through a 70 µm cell strainer and 
likewise suspended for counting.
A cell suspension of 100 µL of cells from spleen and bone marrow was stained with a 
mix of superficial fluorochrome-conjugated antibodies mix prepared in MACS buffer 
at 4°C for 30 minutes in the dark. Cells were washed twice and resuspended with 
MACS buffer if analysed immediately, whereas they were fixed/permeabilized (Anti-
Mouse/Rat Foxp3 Staining Set APC) for 30 minutes at 4°C for intracellular staining.
In this case, cells were stained with fluorochrome conjugated–Ki67 antibody in 1× 
permeabilization buffer for 30 minutes at 4°C, washed with 1× permeabilization 
buffer and resuspended in MACS buffer.
Antibodies for the following markers were used to identify immune populations: in 
the blood, CD45 was used for identification of total leukocytes, CD3 for T 
lymphocytes, CD19 for B lymphocytes, CD11b for cells of myeloid lineage, Ly6G for 
neutrophils, Ly6C for monocytes (highly expressed on activated while low expressed 
on resting monocytes). In the bone marrow within the CD11b+ cells, the combination 
of the expression of Ly6C versus CD115 allowed to discriminate myeloid precursors 
as follows: Ly6C+CD115+ for monocyte precursors (MP), Ly6C+CD115- for 
granulocyte precursors (GP) and Ly6C-CD115- for granulocyte and monocyte 
precursors (GMP). Within MP, the discrimination between cells positive for Ly6G 
allowed the identification of immature (Ly6G+) or mature (Ly6G-) monocytes. In the 
spleen, in addition of markers used in the blood, macrophages were identified as 
CD11b+F4/80+, while dendritic cells as CD11c+MHCII+.
2.7 Platelet/leukocyte aggregates.
Twenty µL whole blood were stimulated at RT for 5 minutes with 5 μM ADP, then 
200 µL of Cell Blood Lysis Buffer (BD Biosciences) were added for 15 minutes, and 
then samples were stained with saturating concentrations of anti-CD45 (leukocytes), 
anti-CD41 (platelets), and anti-CD14 (monocytes) or anti-Lys6G (neutrophils) or 
isotype controls at RT for 30 minutes in the dark. Aggregates were counted by flow 
FACS “Novocyte3000”. A minimum of 5,000 events were collected in the CD14+ or 
Lys6G+ gate as previously described (Sandrini et al., 2017).
2.8. En face analysis of the aorta and aortic sinus histology 
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2.8.1. En face. Aorta images were captured with a stereomicroscope-dedicated camera 
(IC80 HD camera, MZ6 microscope, Leica Microsystems, Germany), and analysed 
with ImageJ image processing program (Schneider et al., 2012). Two independent 
operators, blinded to the dietary treatments, quantified atherosclerosis extent as 
percentage of area covered by plaque.
2.8.2. Aortic sinus histology. Hearts were removed, fixed in 10% formalin and 
processed as previously described (Vik et al., 2013). Serial cryosections (7 micron 
thick) of the aortic sinus were cut and stained with hematoxylin and eosin (H&E) to 
detect plaque area, calculated as the mean area of those sections showing the three 
cusps of the aortic valves. The Nanozoomer S60 (Hamamatsu Photonics, Japan) 
scanner was used to acquire digital images that were subsequently processed with the 
NDP.view2 software (Hamamatsu Photonics, Japan). Two blinded operators to 
dietary treatments quantified plaque size.
2.9. Liver, abdominal WAT, spleen and kidney histology. Formalin fixed 
organs/tissues were dehydrated in a graded scale of ethanol, and paraffin embedded 
(Howard et al., 2018). Sections (4 micron thick) were cut and stained with H&E. 
Perls’ iron staining was used to confirm the presence of hemosiderin in kidney and 
liver. All histological and histochemical f atures were assessed by a veterinary 
pathologist blinded to treatments.
2.10. Skin histology. At sacrifice, skin biopsies were excised from the thoracic 
region, dissected in smaller fragments, and processed for light microscopy analysis. 
For each animal, skin biopsies were divided in both fragments of 5×5 mm and 2×2 
mm. 
Fragments of 5×5 mm were immersion-fixed in 4% paraformaldehyde buffered with 
Phosphate Buffered Saline (PBS) 0.1 M (pH 7.4) for 5 hours at room temperature, 
dehydrated with ethanol and paraffin embedded. Four µm serial sections were stained 
with H&E to observe skin morphology at the structural level.
For transmission electron microscopy, skin specimens of 2×2 mm were processed as 
previously described (Arnaboldi et al., 2015). Semithin sections, 2 µm thick, were 
stained with toluidine blue.
All sections were observed with a Nikon Eclipse E600 microscope equipped with a 
Nikon digital camera DXM1200 (Nikon, Tokyo, Japan).
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2.11. RNA extraction and cDNA synthesis. Total RNA was isolated from mouse 
tissues and extracted as previously described (Manzini et al., 2018). RNA was 
quantified and purity was checked, and 1 μg RNA was retrotranscribed to cDNA, as 
described (Manzini et al., 2015). Possible gDNA contamination was ruled out by 
running a PCR on 20 ng of cDNA/RNA with a primer pair producing two amplicons 
of different size on cDNA (193 bp) and gDNA (677 bp). Conditions as follows: 95 °C 
for 3 min, followed by 35 cycles of 30 s at 95 °C, 30 s at 58.5 °C, 45 s at 72 °C for 45 
s, followed by a final amplification step of 5 min at 72 °C, with primers 
mmu_Srp14_f: 5’-GGAGGCTTCTGCTGACGGCG-3’ and mmu_Srp14_r: 5’- 
GGGCTCGAGGCCCTCCACA-3’.
2.12. Quantitative PCR. Twenty ng of cDNA were used as template for each qPCR 
reaction, performed on a CFX Connect thermal cycler with iTAQ Universal Sybr 
Green Supermix. Standard fast cycling conditions were used, with 300 nM primer 
pairs detailed in Supplementary Table 1. A final melting curve analysis was always 
performed. Fold changes relative to Control group were calculated with the ΔΔCt 
method (Livak and Schmittgen, 2001). The gene cyclophilin A (Ppia) was used as 
reference gene.
2.13. Statistical analyses. Statistical analyses are detailed for each individual analysis 
in the appropriate figure or table caption. The threshold for statistical significance was 
set at p = 0.05. Analyses were performed with R, version 3.3.3 (R Core Team, 2017), 
with packages reshape (Wickham, 2007) and PMCMR for Kruskal-Wallis Conover’s 
post hoc (Pohlert, 2014).
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2.14. Materials
Item Type Supplier City Country
Scobis uno Animal bedding Mucedola Settimo Milanese Italy
Adjusted calories 42% from 
fat, 0.2% cholesterol Animal diet Mucedola Settimo Milanese Italy
Anti-mouse CD45 FITC-
conjugated COD:553079 Antibody BD bioscience Franklin Lakes USA
Anti-mouse CD3 PerCP-
Cy5.5-conjugated 
COD:560527
Antibody BD bioscience Franklin Lakes USA
Anti-mouse CD19 PE-
CF594-conjugated 
COD:562329
Antibody BD bioscience Franklin Lakes USA
Anti-mouse CD11b APC-
Cy7-conjugated 
COD:561039
Antibody BD bioscience Franklin Lakes USA
Anti-mouse CD115 PE-
conjugated COD:565249 Antibody BD bioscience Franklin Lakes USA
Anti-mouse Gr-
1(Ly6C/Ly6G) BV605-
conjugated COD:563299
Antibody BD bioscience Franklin Lakes USA
Anti-mouse F4/80 Af647-
conjugated COD:565854 Antibody BD bioscience Franklin Lakes USA
Anti-mouse MHCII BV650-
conjugated COD:563415 Antibody BD bioscience Franklin Lakes USA
Anti-mouse CD11c BV786-
conjugated COD:563735 Antibody BD bioscience Franklin Lakes USA
Anti-mouse Ki67 V450-
conjugated COD:561281 Antibody BD bioscience Franklin Lakes USA
FITC Rat Anti-Mouse CD41 
COD: 553848 Antibody BD bioscience Franklin Lakes USA
PE Rat Anti-Mouse CD45 Antibody BD Pharmingen San Jose USA
PE Rat anti-Mouse CD14 Antibody BD Pharmingen San Jose USA
Biotin anti-mouse Ly-6G 
Antibody Antibody eBiolegend San Diego USA
Anti-mouse CD206 PECy7-
conjugated COD:25-2069-
41
Antibody eBioscience Waltham USA
Cholesterol assay - COD:CP 
A11 A01634 Assay/kit ABX Diagnostics Montpellier France
Tryglycerides assay - 
COD:CP A11 A01640 Assay/kit ABX Diagnostics Montpellier France
High Capacity cDNA 
Reverse Transcription Kit 
COD:4368814
Assay/kit Applied Biosystems Foster City USA
Phospholipids assay Assay/kit B.L. Chimica Concorezzo Italy
iTAQ Universal Sybr Green 
Supermix Assay/kit Bio-Rad Segrate Italy
Anti-Mouse/Rat Foxp3 
Staining Set APC COD:77-
5775-40
Assay/kit eBioscience Waltham USA
Foxp3 / Transcription 
Factor Staining Buffer Set Assay/kit eBioscience Waltham USA
Clauss Fibrinogen Assay/kit Futura System Roma Italy
NucleoSpin RNA extraction 
kit Assay/kit Macherey-Nagel Duren Germany
PCR primer Assay/kit MWG Ebersberg Germany
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Vectastain Elite ABC-
Peroxidase Staining kit Assay/kit
Vector 
Laboratories Burlingame USA
Mayer's hematoxylin Chemical Bio-Optica Milano Italy
Eosin Y alcoholic solution Chemical Bio-Optica Milano Italy
1-step Fix/Lyse solution 
COD:00-5333-54 Chemical eBioscience Waltham USA
Red Cell Blood Lysis Buffer 
COD:00-4300-54 Chemical eBioscience Waltham USA
Durcupan Chemical Fluka Milano Italy
OCT Chemical Sakura Finetek Alphen aan den Rijn
The 
Netherlands
Other chemicals Chemical Sigma-Aldrich St. Louis USA
3,3'-diaminobenzidine 
substrate (DAB) Chemical
Vector 
Laboratories Burlingame USA
Isoflurane Drug Merial Animal Woking UK
Ultra Touch Glucometer Instrument LifeScan Milano Italy
Miniplast sampling tubes 
for blood citology Plasticware LP Italiana Milano Italy
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3. Results.
3.1. Fenretinide treatment reduced weight gain without lowering food intake. At 
randomization (day 0), the body weight of the two EKO groups was comparable, as 
well as that of WT groups: EKO-Ctrl mice weighed 19.4±0.9 g and EKO-Fen 
19.4±0.7 g (p=0.90); the weight of WT-Ctrl was 17.2±0.9 g and that of WT-Fen was 
17.4±1.1 g (p=0.94). The growth curves of the four groups during the experimental 
study are shown in Figure 1A. Fenretinide treatment reduced the weight gain of both 
EKO and WT mice, with differences that reached statistical significance vs their 
respective controls starting from day 52 and day 61 of treatment, respectively. At 
sacrifice, the mean body weight of EKO-Fen was 10.0% lower than that of EKO-Ctrl 
(p=1.3×10-5) and WT-Fen mice weighed 16.5% less than WT-Ctrl (p=0.007). This 
reduction was paralleled by a strong decrease of WAT. Indeed, the abdominal WAT, 
used as a proxy, showed a strong reduction in both WT-Fen (-58.1%) and EKO-Fen (-
74.8%) mice (Supplementary Figure 1). 
Food and water intake were periodically monitored (Figure 1B, 1D). Daily food 
intake, normalized to body weight, was comparable between EKO-Ctrl and EKO-Fen 
(0.121±0.02 and 0.123±0.02 g/g body weight, respectively, p=0.37, Figure 1C). 
Conversely, food intake of WT-Fen mice was about 12% higher than that of WT-Ctrl 
mice (0.134±0.01 vs 0.119±0.01 g/g body weight, p=0.008, Figure 1C).
From the beginning of the study, an increased water intake was recorded in 
fenretinide-treated mice (Figure 1D), resulting in an higher normalized daily water 
intake in both fenretinide-treated groups, being 0.183±0.02 ml/g body weight in 
EKO-Fen vs 0.143±0.01 in EKO-Ctrl (p=0.0002), and 0.175±0.04 in WT-Fen vs 
0.145±0.01 in WT-Ctrl (p=0.0008) (Figure 1E). 
3.2. Fenretinide treatment lowered plasma glucose levels in EKO mice. At 
baseline, after 5 hours fast, lower glucose levels were detected in EKO-Fen mice 
(118.8±33.4 mg/dl) compared with EKO-Ctrl mice (147.6±20.7 mg/dl, p=0.006) 
(Figure 2A). During the glucose challenge, the mean glucose concentrations were 
lower in treated mice than in controls, but statistical significance was not attained, 
also when considering the area under the curve (AUC, p=0.065) (Figure 2B). At the 
end of the challenge, i.e. at 100 minutes, and at the regaining of baseline at 125 
minutes, glucose levels returned to be significantly lower in EKO-Fen than in EKO-
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Ctrl mice (129.6±22.8 vs 157.6±21.5 mg/dl at 125 minutes, p=0.001), consistent with 
pre-challenge values.
GLUT-4 (Slc2a4 gene) expression was almost twofold higher in the WAT of EKO-
Fen, with respect to EKO-Ctrl (p=1.7×10-5) (Figure 3A). Additionally, Resistin (Retn 
gene) expression in WAT was almost fivefold decreased in EKO-Fen with respect to 
EKO-Ctrl (p=0.033) (Figure 3A).
Histological features in WAT were not different among groups. In the liver, a severe 
decrease in the amount of glycogen stored in the cytoplasm of hepatocytes was 
observed in EKO-Fen compared to EKO-Ctrl (p=5.1×10-4) (Supplementary Figure 2); 
a mild decrease was also observed in WT-Fen mice compared to WT-Ctrl 
(Supplementary Table 5).
3.3. Fenretinide reduced plasma lipid concentrations in EKO. At the end of 
treatment, plasma lipid concentrations were measured in EKO mice after 5 hours 
fasting. Fenretinide treatment strongly lowered plasma lipid levels (Figure 4A). Total 
cholesterol (TC) levels were reduced by 20.1% (1,133.5±153.3 mg/dl in EKO-Ctrl vs 
904.5±169.37 mg/dl in EKO-Fen, p=8.0×10-5) and this decrease was mostly 
attributable to a cholesterol reduction in the LDL fraction, as assessed by FPLC 
analysis (Figure 4B). Triglyceride (TG) levels were also dramatically reduced (-
66.8% vs EKO-Ctrl), averaging at 114.6±38.0 in EKO-Ctrl and 38.0±14.9 mg/dl in 
EKO-Fen (Figure 4A, p=2.1×10-11). This reduction affected all lipoprotein classes 
(Figure 4C). Last, phospholipids also showed a reduction with fenretinide treatment (-
20.1%), averaging at 350.8±45.0 mg/dl in EKO-Ctrl and 280.09±143.2 mg/dl in 
EKO-Fen (p=0.042) (Figure 4A).
Histological examination of liver showed that the high-fat diet in EKO-Ctrl mice 
caused steatosis, which was severely lowered by Fenretinide treatment (p=0.0041) 
(Supplementary Figure 2). Steatosis was not observed in WT-Ctrl and WT-Fen mice 
(Supplementary Table 5).
In the liver of treated animals, fenretinide caused a threefold induction of Hmgcr 
(p=0.016) and a small, but significative downregulation of SR-B1 (Scarb1 gene, 
p=6.6×10-4) (Figure 3B). No significant changes in the expression of the other 
investigated genes relevant to lipid/lipoprotein metabolism were observed (Figure 
3B).
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3.4. Fenretinide dramatically worsened atherosclerosis development in EKO 
mice. Atherosclerotic plaque development was measured on aortas cut lengthwise, as 
percentage of area occupied by plaques, in the three aortic districts. In each segment, 
plaque development in fenretinide-treated mice was higher with respect to control 
mice (Figure 5A). Specifically, plaque development was 32.1%, 190.8% and 129.7% 
higher in EKO-Fen with respect to EKO-Ctrl at the aortic arch (p=0.0003), thoracic 
(p=2.6×10-9) and abdominal aorta (p=1.3×10-5), respectively (Figure 5B).
Plaque extent was further quantified at the aortic sinus (Figure 5C,D) and provided 
similar results: plaque area was increased by 50.8% in EKO-Fen with respect to 
EKO-Ctrl (p=3.0×10-7).
3.5. Fenretinide dramatically increased blood leukocytes and affected 
erythrocyte and platelet counts. 
Total white blood cell counts were significantly increased upon fenretinide treatment, 
in both EKO (+131.2%) and WT mice (+112.6%) (Figure 6A). Monocytes and 
eosinophils were unchanged in control and treated mice, but lymphocyte counts were 
significantly higher, over twofold increased, in both EKO and WT mice (Figure 6B). 
Also neutrophils were increased upon fenretinide treatment, even if the difference was 
significant only in WT mice (Figure 6B).
Erythroid parameters decreased in treated animals either in EKO (RBC: -25.0%, HGB 
-19.8%, HCT -6.7%) or in WT mice (RBC -11.3%, HGB -13.6%, HCT -10.0%). All 
the differences above were statistically significant, except for the HCT of EKO mice 
(Figure 6C). In EKO-Fen mice, RBC were macrocytic (MCV +19.0%) and 
hypochromic (MCHC -14.4%) compared with EKO-Ctrl. In WT mice, RBC were 
hypochromic (MCHC -3.5%) but no changes in the MCV were observed (Figure 6C). 
Platelet counts were lower in treated mice compared with controls in both groups, but 
this decrease was significant only in EKO mice (-19.1%) (Figure 6D). 
In bone marrow, an increase of the myeloid:erythroid ratio was found in both groups, 
but a significant difference was reached only in WT mice (+39.4%). No other 
significant difference was found, although in both groups lymphocytes and plasma 
cells showed a moderate reduction in treated mice. The percentage of the proliferating 
pools of erythroid and myeloid cells was not significantly affected by treatment, but 
showed an opposite trend in EKO and WT mice (Figure 6E).
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3.6. Immunophenotyping of blood, bone marrow and spleen
The increase of total counts of circulating leukocytes (CD45+) upon fenretinide 
treatment was further confirmed by flow cytometry in both EKO and WT mice (+67% 
and +139%, respectively, Figure 7A, 7D). 
In EKO mice this effect was mainly due to the rise of both T (CD3+) and B (CD19+) 
lymphocytes (Figure 7B). Within monocytes, fenretinide treatment in EKO also 
increased the relative amount of activated versus resting cells (Ly6Chi versus Ly6Clo) 
(Figure 7C). In WT animals, fenretinide treatment caused a significant increase in all 
leukocyte subpopulations (Figure 7E).
The analysis of bone marrow did not unmask significant differences in the total count 
of leukocytes (CD45+/femur, Figure 7G) in both EKO and WT mice upon fenretinide 
treatment. However, the relative amount of myeloid cells (CD11b+) over the total 
leukocytes revealed an enrichment of this cell type in fenretinide treated animals of 
both mouse lines (Figure 7H). In addition, in EKO mice fenretinide treatment 
significantly increased the relative amount of monocyte progenitors (MP) (Figure 
7I,J) and showed a significant impairment of monocyte maturation (Figure 7K). No 
variations by treatment were instead observed in WT mice (Figure 7L,M).
In the spleen, absolute counts of myeloid cells (CD11b), dendritic cells, macrophages, 
T and B lymphocytes, and consequently of total leukocytes were unaltered in EKO 
mice (Figure 7N,P). An increase of leukocyte subsets was instead overall observed in 
the spleen of WT mice, that was significant for myeloid cells (+42.1%), dendritic 
cells (+74.7%), macrophages (+53.1%), B lymphocytes (+58.2), total leukocytes 
(+48.9%), (Figure 7O,Q). When cellular count was corrected for spleen weight, the 
number of all main classes of leukocytes was significantly decreased in EKO mice 
(Figure 7R,T: -54.9%, -48.3%, -52.9%, -60.8%, -60.9%, -59.8% for myeloid, 
dendritic cells, macrophages, T and B lymphocytes, total leukocytes, respectively) 
whereas no differences were detected in WT mice (Figure 7S,U). These findings are 
in accordance with the morphological changes observed in both genotypes following 
fenretinide treatment. In WT mice, spleen weight was moderately increased (90±20 
mg and 120±40 mg in WT-Ctrl and WT-Fen, respectively; p=0.035), whereas in EKO 
mice the spleen appeared markedly enlarged (211±67 mg and 597±159 mg in EKO-
Ctrl and EKO-Fen, respectively; p=7.8×10-12) (Supplementary Figure 1). In WT-Fen, 
histological examination showed an increased, although not significant, incidence of 
extramedullary hematopoiesis, characterized by the presence of hematopoietic cells 
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expanding the red pulp (Supplementary Table 5). On the contrary, in EKO-Fen mice, 
compared to EKO-Ctrl mice, spleen parenchyma showed the presence of severe 
extramedullary hematopoiesis (p=0.008) and a marked follicular atrophy (p=0.006) 
(Supplementary Table 2 and Figure 8A,B). Extramedullary hematopoiesis was also a 
constant finding in the liver of EKO-Fen (9 out of 10 animals), but not in that of 
EKO-Ctrl (1 out of 10 mice, p=0.0011) (Figure 8C,D).
3.7. Fenretinide increased erythrocyte destruction.
Histological findings in kidney and liver indicated that fenretinide treatment to EKO 
mice accelerated erythrocyte turnover. In fact, hemosiderosis was absent in the kidney 
and liver of EKO-Ctrl and WT mice (Supplementary Table 5), whereas in EKO-Fen 
the presence of hemosiderin was observed multifocally within the cytoplasm of 
tubular epithelial cells in the proximal convoluted tubules of the kidney in all animals 
(Figure 8G-L and Supplementary Table 3) and in the cytoplasm of Kupffer cells in 
the liver of 9 out of 10 mice (Figure 8E,F).
3.8. Functional fibrinogen
A significant increase in the plasma fibrinogen activity was observed in EKO-Fen 
mice, with respect to EKO-Ctrl (+48.7%, p=0.0371) (Supplementary Figure 3). The 
same trend was observed in WT mice (+31.0%), although it did not reach statistical 
significance.
3.9. Platelet/leukocyte aggregates.
In total blood, the percentage of platelet-leukocyte aggregates was greater in EKO-
Ctrl compared with WT-Ctrl mice (p=0.0338) (Supplementary Figure 4A). This 
parameter was not modified by fenretinide treatment in WT mice, whereas it was 
strongly lowered in EKO animals, where it became comparable to that of WT mice 
(Supplementary Figure 4A).
Remarkably, the analysis of leukocyte subsets showed that the percentage of 
monocyte & neutrophil-platelet aggregates was much higher in EKO-Ctrl vs WT-Ctrl 
mice (+112.81%, p=0.00107) and fenretinide treatment only slightly modified these 
values, in both genotypes (p>0.05, Figure 9A). 
When considering monocyte-platelet aggregates alone, untreated mice of both 
genotypes showed similar values (Figure 9B). Fenretinide tended to decrease the 
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number of monocyte-platelet aggregates in WT mice (from 25.4±7.2% to 15.1±3.8%, 
p=0.058), whereas in EKO mice, the treatment significantly increased the number of 
aggregates (+42.3%, from 27.8±6.7% to 42.3±6.8%, p=0.0081) (Figure 9B).
Finally, the percentage of circulating neutrophil-platelet aggregates was greater in 
EKO-Ctrl compared to WT-Ctrl mice (p=0.0159). Fenretinide treatment did not cause 
any significant variation in the two genotypes (Supplementary Figure 4B).
3.10 Other histological findings. 
In lungs, moderate to severe lesions characterized by the presence of foamy 
macrophages were a constant finding in EKO-Fen mice (Supplementary Figure 5), 
whereas they were absent in EKO-Ctrl as well as in all WT animals (Supplementary 
Table 5). Additionally, cholesterol crystals were occasionally observed only in EKO-
Fen animals.
Morphological analysis did not show any significant difference between the skin of 
treated and untreated WT mice (Supplementary Table 4). In both the experimental 
groups, indeed, the epidermis appeared build-up of ordinated overlapped layers of 
cells and in the dermis there were no signs of alteration. The presence of foam cells 
was detected only in treated and untreated EKO mice (p= 0.000113 vs WT mice). 
Other morphological alterations were also visible, although shared almost equally in 
EKO-Ctrl and EKO-Fen animals (Supplementary Table 4 and Supplementary Figure 
6)
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4. Discussion
The main result of the present study is that, despite the favourable metabolic effects 
exerted by fenretinide treatment on glucose tolerance, fat mass accumulation, liver 
steatosis and, most importantly, on the plasma lipid levels, the treatment resulted into 
an unpredictable worsening of atherosclerosis. In the study, apoE-deficient mice were 
used, as they spontaneously develop hypercholesterolemia and atherosclerotic lesions 
that, alike human counterparts, stem from early fatty streaks and develop into 
advanced and complex lesions (Plump et al., 1992; Nakashima et al., 1994). When fed 
high-fat diet, lesion formation is greatly accelerated. Further, this dietary treatment 
also results in an impaired glucose metabolism (Nakashima et al., 1994; Su et al., 
2006). Wild-type mice on the same background were also included in the study to 
assess genotype-specific biases.
Fenretinide pharmacodynamics and toxicology have been known for a long time, and 
a dietary formulation is possible (McCormick et al., 1987; Slawin et al., 1993; 
Preitner et al., 2009). A formulation of 1 mg fenretinide per g of diet has been chosen 
as proof-of-principle. A long-term treatment (12 weeks) has already been documented 
in diet-induced obese mice fed with high fat diet supplemented with the selected 
fenretinide dosage (0.1% w/w) and even longer treatment times have been used 
(Preitner et al., 2009). As readout of the treatment, the hepatic expression of Cyp26a1, 
a cytochrome involved in the metabolism of retinoids, was upregulated fourfold in the 
liver of fenretinide-treated mice (Figure 3B).
The possible effects of fenretinide treatment on body weight, fat mass accumulation, 
glucose metabolism and plasma lipid levels, still untested in the apoE-deficient 
model, were investigated in the present study. The reduction of body weight gain 
following fenretinide treatment has been thoroughly documented in wild-type and in 
genetically obese mice (Preitner et al., 2009; Koh et al., 2012; Mcilroy et al., 2013; 
Shearer et al., 2015). Consistent with these findings, in the present study fenretinide 
treatment reduced body weight gain and fat mass in both apoEKO and wild-type 
mice. This mostly occurs via the inhibition of adipogenesis through prevention of 
C/EBPβ transcription (Mcilroy et al., 2016). The treatment was not expected to alter 
the food intake (Shearer et al., 2015), and indeed food intake was unchanged in EKO 
and negligibly increased in WT mice.
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It has also been demonstrated how fenretinide displays insulin-sensitizing and anti-
diabetic effects in mice and overweight humans (Bikman et al., 2012). Reportedly, the 
inhibition of ceramide pathway biosynthesis enhances insulin sensitivity (Aerts et al., 
2007),  and fenretinide has been found to be inhibiting dihydroceramide desaturases, 
that catalyse the final step in de novo ceramide synthesis (Rahmaniyan et al., 2011). 
Likewise, in the present study fenretinide treatment resulted in significantly lower 
basal glycaemia in treated vs untreated EKO mice. Furthermore, throughout the whole 
glucose tolerance test, treated EKO mice always showed average glucose levels 
trending towards 10-20% lower values than untreated mice. Slc2a4 (GLUT4) 
expression levels correlate with whole-body insulin-mediated glucose homeostasis 
(Atkinson et al., 2013). Moreover, insulin-resistant glucose transport in adipocytes 
from obese and diabetic subjects correlates with reduced GLUT4 expression (Berger 
et al., 1989). Accordingly, we found that Slc2a4 expression was almost twofold 
higher in the WAT of EKO-Fen, with respect to controls.
In mice, the main source of resistin (Retn gene) is white adipose tissue (Jamaluddin et 
al., 2012). Even if resistin was first described as a factor contributing to the 
development of insulin resistance and diabetes in humans, there is no clear consensus 
yet regarding its exact contribution to obesity and insulin sensitivity. However, 
resistin serum levels are positively associated with increased acute coronary 
syndrome (Jamaluddin et al., 2012). Further, several studies support a positive 
correlation between elevated serum resistin and obesity or impaired glucose tolerance 
(Malo et al., 2011; Luo et al., 2012). We found that Retn gene expression in WAT 
was almost fivefold decreased in EKO-Fen with respect to EKO-Ctrl.
Another reported beneficial effect of fenretinide treatment is the reduction of plasma 
lipids, including total cholesterol, triglycerides and free fatty acids, in obese mice fed 
a high fat diet (Koh et al., 2012). This holds true also in EKO mice, where fenretinide 
was able to dramatically and significantly reduce total cholesterol (-20.2%), 
triglycerides (-66.9%) and phospholipids (-20.1%). No relevant variations in the 
expression of genes involved in lipid metabolism were found, except for a threefold 
increase of Hmgcr, the rate-limiting enzyme in cholesterol synthesis. Additionally, 
hepatic steatosis and glycogen accumulation, typically observed in EKO mice on high 
fat diet, were greatly reduced by treatment.
Given the wealth of favourable preliminary data, the main objective of the present 
study was the evaluation of a possible effect of fenretinide on atherosclerosis 
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development. Strikingly, and in apparent contrast with the data discussed above, the 
treatment resulted in a marked increase of the extent of atherosclerotic lesions in all 
aortic districts, including the aortic sinus. This result may not be explained taken into 
account the data reviewed so far, especially considering the reduction of plasma lipid 
levels. While it is true that there was a remarkable absolute reduction of total 
cholesterol (-229 mg/dl), plasma cholesterol levels remained very high, a 
characteristic feature of this mouse model. Nonetheless, this reduction in the lipid 
levels, however limited, should be paralleled by a reduced plaque development 
(Parolini et al., 2017).
The most remarkable macroscopic feature of EKO mice treated with fenretinide was 
an abnormally enlarged spleen. Also in WT mice the treatment resulted in 
significantly heavier spleens, although this variation was less dramatic. Whereas in 
WT mice this weight increase was paralleled by an increase in the leukocyte content, 
in EKO mice the augmented organ mass was not associated to a change of total 
leukocyte number, as well as of individual leukocyte subpopulations, that were totally 
comparable in treated and untreated EKO mice. The histological analysis supported 
these findings, being the spleen of treated EKO mice characterized by small and 
atrophic follicles. Extramedullary haematopoiesis was detected in fenretinide treated 
WT mice as well as EKO mice. In these latt r, the red pulp was strongly expanded, 
thus explaining, at least in part, the enlargement of this organ. Only in EKO treated 
mice, extramedullary haematopoiesis was observed also in the liver. 
Blood cytology analysis showed that in both EKO and WT mice, the treatment 
induced a decrease of the erythroid mass. This decrease seemed to be due to a reduced 
production of RBC in WT mice, which had a normocytic hypochromic pattern. 
Conversely, in EKO mice the macrocytic hypochromic pattern was consistent with 
active bone marrow regeneration, generally associated to blood loss or hemolysis. 
Histopathological findings strongly supported this latter hypothesis, showing in the 
kidney, as well as in hepatic Kupffer cells, a massive deposition of hemosiderin 
pigment, coming from disintegrating erythrocytes. Erythrolysis was a condition found 
only in EKO mice and possibly consequent to the severe hypercholesterolemia that 
has been shown to increase the osmotic fragility of RBC (Fessler et al., 2013). In 
addition, fenretinide treatment is associated to an augmented ROS production 
(Cuperus et al., 2010) which in turn reduces RBC deformability (Diederich et al., 
2018). These two effects synergize in EKO-Fen only, leading to peripheral hemolysis.
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Fenretinide treatment caused a dramatic increase of circulating leukocytes both in WT 
and EKO mice. All leukocyte classes contributed to this rise, with lymphocytes 
playing the major role. A similar response to fenretinide treatment has been recently 
reported in wild-type mice receiving higher doses of the drug (Cook et al., 2018). 
Being fenretinide tested in the clinic for the treatment of solid and blood 
malignancies, it is difficult to translate this finding in humans. 
Platelet counts were lower in EKO compared to WT mice. In EKO however, large 
platelet clumps were frequently found in blood, suggesting that this decrease is likely 
due to an hyperactivation of platelets. Fenretinide treatment lowered platelet counts in 
both genotypes, although this trend was particularly severe, and statistically 
significant, only in EKO mice.
The hematological alterations discussed above, consequent to fenretinide treatment 
could at least partially explain the atherosclerosis worsening observed in EKO mice.
The peripheral destruction of erythrocytes observed in EKO treated mice has been 
reported to release inflammatory mediators, resulting in a state of general 
inflammation (Randolph, 2009). Additionally, the percentage of circulating activated 
monocytes was increased by treatment. Monocytes are the primary inflammatory cell 
type that infiltrates early atherosclerotic plaques, and their recruitment drives disease 
progression (Randolph, 2009). Interestingly, FACS analyses revealed an increase in 
the bone marrow of myeloid precursors, including immature monocytes, in EKO 
treated mice, suggesting an accelerated myelopoiesis and an impaired maturation of 
these lineages. Of note, increased bone marrow myelopoiesis and extramedullary 
myelopoiesis have been positively associated with atherosclerosis (Yvan-Charvet et 
al., 2010; Murphy et al., 2011); in addition, our observation that circulating activated 
monocytes are increased in treated EKO further links the immunomodulation induced 
by fenretinide to atherosclerosis development. Further, the greater percentage of 
monocyte/platelet aggregates detected in treated EKO mice might contribute to the 
marked atherosclerosis in these mice. Indeed, activated platelets bound circulating 
monocytes, promoting atherosclerotic plaque formation and development (Huo et al., 
2003). In particular, both activated platelets and platelet-monocyte aggregates induce 
the adhesion of leukocytes to the endothelium, the recruitment of monocytes in 
atherosclerotic lesion, and they increase cholesteryl ester accumulation in monocyte-
derived macrophages, as well as the differentiation of CD34+ myeloid cells into foam 
cells (Daub et al., 2006).
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Finally, the increased fibrinogen activity in EKO mice treated with fenretidine and the 
greater concomitant increase in atherosclerosis is coherent with data obtained in 
various epidemiological studies and animal models (Handa et al., 1989; Koopman et 
al., 1997; Uner et al., 2018).
In conclusion, all these evidences demonstrate that fenretinide treatment, in spite of 
positive metabolic effects, severely altered blood cell turnover, resulting in a 
worsening of atherosclerosis development in an atherosclerosis-prone mouse model of 
widespread use (Emini Veseli et al., 2017). Even if more work is needed to 
demonstrate to what extent they can be translated into the human setting, these results 
strongly suggest careful selection and monitoring of patients undergoing fenretinide 
treatment.
 
Page 25 of 57
British Pharmacological Society
British Journal of Pharmacology
For Peer Review
5. Author Contributions
Marco Busnelli: Conceived the study, managed the study, evaluated atherosclerosis 
development, wrote the paper
Stefano Manzini: Conceived the study, managed the study, performed molecular 
biology experiments, performed statistical analyses, wrote the paper
Fabrizia Bonacina: Performed FACS experiments
Sabina Soldati: Performed extensive histological analyses
Silvia Stella Barbieri: Assayed leukocyte-platelet interactions, assayed functional 
fibrinogen
Patrizia Amadio: Assayed leukocyte-platelet interactions, assayed functional 
fibrinogen
Leonardo Sandrini: Assayed leukocyte-platelet interactions, assayed functional 
fibrinogen
Francesca Arnaboldi: Performed skin histology
Elena Donetti: Performed skin histology
Reijo Laaksonen: Helped conceiving the study, proofread the manuscript
Saverio Paltrinieri: Performed extensive hematological analyses and bone marrow 
cytology
Eugenio Scanziani: Performed extensive histological analyses
Giulia Chiesa: Conceived the study, managed the study, raised funds for the study, 
supervised all experiments, critically revised the manuscript
Page 26 of 57
British Pharmacological Society
British Journal of Pharmacology
For Peer Review
6. Acknowledgements
This work was funded by the European Community’s Seventh Framework 
Programme (FP7/2012–2017) RiskyCAD, grant no. 305739 (G.C.), by Fondazione 
CARIPLO (2011-0645) (G.C.) and by grants from MIUR Progetto Eccellenza. We 
are grateful to Ms. Elda Desiderio Pinto for administrative assistance. We deeply 
thank Elena Olmastroni for advices and checks on statistical analyses and we thank 
Dr. Cinzia Parolini for technical support. Part of this work was carried out at 
NOLIMITS, an advanced imaging facility established by the Università degli Studi di 
Milano. Dr. Leonardo Sandrini is supported by the 32nd cycle Ph.D. program in 
“Scienze farmacologiche sperimentali e cliniche”, Università degli Studi di Milano.
Page 27 of 57
British Pharmacological Society
British Journal of Pharmacology
For Peer Review
7. References
Aburasayn, H., Batran, R. Al, and Ussher, J.R. (2016). Targeting ceramide 
metabolism in obesity. Am. J. Physiol. Endocrinol. Metab. 311: E423-35.
Aerts, J.M., Ottenhoff, R., Powlson, A.S., Grefhorst, A., Eijk, M. van, Dubbelhuis, 
P.F., et al. (2007). Pharmacological inhibition of glucosylceramide synthase enhances 
insulin sensitivity. Diabetes 56: 1341–9.
Amadio, P., Colombo, G.I., Tarantino, E., Gianellini, S., Ieraci, A., Brioschi, M., et al. 
(2017a). BDNFVal66met polymorphism: a potential bridge between depression and 
thrombosis. Eur. Heart J. 38: 1426–1435.
Amadio, P., Tarantino, E., Sandrini, L., Tremoli, E., and Barbieri, S.S. (2017b). 
Prostaglandin-endoperoxide synthase-2 deletion affects the natural trafficking of 
Annexin A2 in monocytes and favours venous thrombosis in mice. Thromb. Haemost. 
117: 1486–1497.
Arnaboldi, F., Busnelli, M., Cornaghi, L., Manzini, S., Parolini, C., Dellera, F., et al. 
(2015). High-density lipoprotein deficiency in genetically modified mice deeply 
affects skin morphology: A structural and ultrastructural study. Exp. Cell Res. 338: 
105–12.
Atkinson, B.J., Griesel, B.A., King, C.D., Jos y, M.A., and Olson, A.L. (2013). 
Moderate glut4 overexpression improves insulin sensitivity and fasting 
triglyceridemia in high-fat diet-fed transgenic mice. Diabetes 62: 2249–2258.
Berger, J., Biswas, C., Vicario, P.P., Strout, H.V., Saperstein, R., and Pilch, P.F. 
(1989). Decreased expression of the insulin-responsive glucose transporter in diabetes 
and fasting. Nature 340: 70–2.
Berry, D.C., DeSantis, D., Soltanian, H., Croniger, C.M., and Noy, N. (2012). 
Retinoic acid upregulates preadipocyte genes to block adipogenesis and suppress diet-
induced obesity. Diabetes 61: 1112–21.
Berry, D.C., and Noy, N. (2009). All-trans-retinoic acid represses obesity and insulin 
resistance by activating both peroxisome proliferation-activated receptor beta/delta 
and retinoic acid receptor. Mol. Cell. Biol. 29: 3286–96.
Bikman, B.T., Guan, Y., Shui, G., Siddique, M.M., Holland, W.L., Kim, J.Y., et al. 
(2012). Fenretinide prevents lipid-induced insulin resistance by blocking ceramide 
biosynthesis. J. Biol. Chem. 287: 17426–37.
Busnelli, M., Manzini, S., Hilvo, M., Parolini, C., Ganzetti, G.S., Dellera, F., et al. 
Page 28 of 57
British Pharmacological Society
British Journal of Pharmacology
For Peer Review
(2017). Liver-specific deletion of the Plpp3 gene alters plasma lipid composition and 
worsens atherosclerosis in apoE-/- mice. Sci. Rep. 7: 44503.
Cook, J.C., Obert, L.A., Koza-Taylor, P., Coskran, T.M., Opsahl, A.C., Ziemek, D., et 
al. (2018). From the Cover: Fenretinide, Troglitazone, and Elmiron Add to Weight of 
Evidence Support for Hemangiosarcoma Mode-of-Action From Studies in Mice. 
Toxicol. Sci. 161: 58–75.
Cooper, J.P., Reynolds, C.P., Cho, H., and Kang, M.H. (2017). Clinical development 
of fenretinide as an antineoplastic drug: Pharmacology perspectives. Exp. Biol. Med. 
(Maywood). 242: 1178–1184.
Cuperus, R., Leen, R., Tytgat, G.A.M., Caron, H.N., and Kuilenburg, A.B.P. van 
(2010). Fenretinide induces mitochondrial ROS and inhibits the mitochondrial 
respiratory chain in neuroblastoma. Cell. Mol. Life Sci. 67: 807–16.
Daub, K., Langer, H., Seizer, P., Stellos, K., May, A.E., Goyal, P., et al. (2006). 
Platelets induce differentiation of human CD34+ progenitor cells into foam cells and 
endothelial cells. FASEB J. 20: 2559–61.
Diederich, L., Suvorava, T., Sansone, R., Keller, T.C.S., Barbarino, F., Sutton, T.R., 
et al. (2018). On the Effects of Reactive Oxygen Species and Nitric Oxide on Red 
Blood Cell Deformability. Front. Physiol. 9: 332.
Emini Veseli, B., Perrotta, P., Meyer, G.R.A. De, Roth, L., Donckt, C. Van der, 
Martinet, W., et al. (2017). Animal models of atherosclerosis. Eur. J. Pharmacol. 816: 
3–13.
Fessler, M.B., Rose, K., Zhang, Y., Jaramillo, R., and Zeldin, D.C. (2013). 
Relationship between serum cholesterol and indices of erythrocytes and platelets in 
the US population. J. Lipid Res. 54: 3177–88.
Handa, K., Kono, S., Saku, K., Sasaki, J., Kawano, T., Sasaki, Y., et al. (1989). 
Plasma fibrinogen levels as an independent indicator of severity of coronary 
atherosclerosis. Atherosclerosis 77: 209–13.
Howard, S.R., Oleari, R., Poliandri, A., Chantzara, V., Fantin, A., Ruiz-Babot, G., et 
al. (2018). HS6ST1 Insufficiency Causes Self-Limited Delayed Puberty in Contrast 
With Other GnRH Deficiency Genes. J. Clin. Endocrinol. Metab. 103: 3420–3429.
Huo, Y., Schober, A., Forlow, S.B., Smith, D.F., Hyman, M.C., Jung, S., et al. (2003). 
Circulating activated platelets exacerbate atherosclerosis in mice deficient in 
apolipoprotein E. Nat. Med. 9: 61–7.
Jamaluddin, M.S., Weakley, S.M., Yao, Q., and Chen, C. (2012). Resistin: functional 
Page 29 of 57
British Pharmacological Society
British Journal of Pharmacology
For Peer Review
roles and therapeutic considerations for cardiovascular disease. Br. J. Pharmacol. 165: 
622–32.
Koh, I., Jun, H.-S., Choi, J.S., Lim, J.H., Kim, W.H., Yoon, J.B., et al. (2012). 
Fenretinide ameliorates insulin resistance and fatty liver in obese mice. Biol. Pharm. 
Bull. 35: 369–75.
Koopman, J., Maas, A., Rezaee, F., Havekes, L., Verheijen, J., Gijbels, M., et al. 
(1997). Fibrinogen and atherosclerosis: a study in transgenic mice. Fibrinolysis and 
Proteolysis 11: 19–21.
Lachance, C., Wojewodka, G., Skinner, T.A.A.A., Guilbault, C., Sanctis, J.B. De, and 
Radzioch, D. (2013). Fenretinide corrects the imbalance between omega-6 to omega-3 
polyunsaturated fatty acids and inhibits macrophage inflammatory mediators via the 
ERK pathway. PLoS One 8: e74875.
Livak, K.J., and Schmittgen, T.D. (2001). Analysis of relative gene expression data 
using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 
402–8.
Luo, R., Li, X., Jiang, R., Gao, X., Lü, Z., and Hua, W. (2012). Serum concentrations 
of resistin and adiponectin and their relationship to insulin resistance in subjects with 
impaired glucose tolerance. J. Int. Med. Res. 40: 621–30.
Mackie, I.J., Kitchen, S., Machin, S.J., Lowe, G.D.O., and Haemostasis and 
Thrombosis Task Force of the British Committee for Standards in Haematology 
(2003). Guidelines on fibrinogen assays. Br. J. Haematol. 121: 396–404.
Malo, E., Ukkola, O., Jokela, M., Moilanen, L., Kähönen, M., Nieminen, M.S., et al. 
(2011). Resistin is an indicator of the metabolic syndrome according to five different 
definitions in the Finnish Health 2000 survey. Metab. Syndr. Relat. Disord. 9: 203–
10.
Manzini, S., Busnelli, M., Parolini, C., Minoli, L., Ossoli, A., Brambilla, E., et al. 
(2018). Topiramate protects apoE-deficient mice from kidney damage without 
affecting plasma lipids. Pharmacol. Res. 141: 189–200.
Manzini, S., Pinna, C., Busnelli, M., Cinquanta, P., Rigamonti, E., Ganzetti, G.S., et 
al. (2015). Beta2-adrenergic activity modulates vascular tone regulation in 
lecithin:cholesterol acyltransferase knockout mice. Vascul. Pharmacol. 74: 114–121.
Marchesi, M., Parolini, C., Caligari, S., Gilio, D., Manzini, S., Busnelli, M., et al. 
(2011). Rosuvastatin does not affect human apolipoprotein A-I expression in 
genetically modified mice: a clue to the disputed effect of statins on HDL. Br. J. 
Page 30 of 57
British Pharmacological Society
British Journal of Pharmacology
For Peer Review
Pharmacol. 164: 1460–8.
McCormick, D.L., Bagg, B.J., and Hultin, T.A. (1987). Comparative activity of 
dietary or topical exposure to three retinoids in the promotion of skin tumor induction 
in mice. Cancer Res. 47: 5989–93.
Mcilroy, G.D., Delibegovic, M., Owen, C., Stoney, P.N., Shearer, K.D., McCaffery, 
P.J., et al. (2013). Fenretinide treatment prevents diet-induced obesity in association 
with major alterations in retinoid homeostatic gene expression in adipose, liver, and 
hypothalamus. Diabetes 62: 825–36.
Mcilroy, G.D., Tammireddy, S.R., Maskrey, B.H., Grant, L., Doherty, M.K., Watson, 
D.G., et al. (2016). Fenretinide mediated retinoic acid receptor signalling and 
inhibition of ceramide biosynthesis regulates adipogenesis, lipid accumulation, 
mitochondrial function and nutrient stress signalling in adipocytes and adipose tissue. 
Biochem. Pharmacol. 100: 86–97.
Mody, N., and Mcilroy, G.D. (2014). The mechanisms of Fenretinide-mediated anti-
cancer activity and prevention of obesity and type-2 diabetes. Biochem. Pharmacol. 
91: 277–86.
Murphy, A.J., Akhtari, M., Tolani, S., Pagler, T., Bijl, N., Kuo, C.-L., et al. (2011). 
ApoE regulates hematopoietic stem cell proliferation, monocytosis, and monocyte 
accumulation in atherosclerotic lesions in mic . J. Clin. Invest. 121: 4138–49.
Nakashima, Y., Plump, A.S., Raines, E.W., Breslow, J.L., and Ross, R. (1994). 
ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the 
arterial tree. Arterioscler. Thromb.  a J. Vasc. Biol. 14: 133–40.
Parolini, C., Bjorndal, B., Busnelli, M., Manzini, S., Ganzetti, G.S., Dellera, F., et al. 
(2017). Effect of Dietary Components from Antarctic Krill on Atherosclerosis in 
apoE-Deficient Mice. Mol. Nutr. Food Res. 61: 1700098.
Parolini, C., Vik, R., Busnelli, M., Bjørndal, B., Holm, S., Brattelid, T., et al. (2014). 
A salmon protein hydrolysate exerts lipid-independent anti-atherosclerotic activity in 
ApoE-deficient mice. PLoS One 9: e97598.
Petersen, M.C., and Shulman, G.I. (2018). Mechanisms of Insulin Action and Insulin 
Resistance. Physiol. Rev. 98: 2133–2223.
Plump, A.S., Smith, J.D., Hayek, T., Aalto-Setälä, K., Walsh, A., Verstuyft, J.G., et 
al. (1992). Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-
deficient mice created by homologous recombination in ES cells. Cell 71: 343–53.
Pohlert, T. (2014). The Pairwise Multiple Comparison of Mean Ranks Package 
Page 31 of 57
British Pharmacological Society
British Journal of Pharmacology
For Peer Review
(PMCMR).
Preitner, F., Mody, N., Graham, T.E., Peroni, O.D., and Kahn, B.B. (2009). Long-
term Fenretinide treatment prevents high-fat diet-induced obesity, insulin resistance, 
and hepatic steatosis. Am. J. Physiol. Endocrinol. Metab. 297: E1420-9.
R Core Team (2017). R: A Language and Environment for Statistical Computing.
Rahmaniyan, M., Curley, R.W., Obeid, L.M., Hannun, Y.A., and Kraveka, J.M. 
(2011). Identification of dihydroceramide desaturase as a direct in vitro target for 
fenretinide. J. Biol. Chem. 286: 24754–64.
Randolph, G.J. (2009). The fate of monocytes in atherosclerosis. J. Thromb. Haemost. 
7 Suppl 1: 28–30.
Sandrini, L., Ieraci, A., Amadio, P., Popoli, M., Tremoli, E., and Barbieri, S.S. 
(2017). Apocynin Prevents Abnormal Megakaryopoiesis and Platelet Activation 
Induced by Chronic Stress. Oxid. Med. Cell. Longev. 2017:.
Schneider, C.A., Rasband, W.S., and Eliceiri, K.W. (2012). NIH Image to ImageJ: 25 
years of image analysis. Nat. Methods 9: 671–5.
Shearer, K.D., Morrice, N., Henderson, C., Reekie, J., Mcilroy, G.D., McCaffery, 
P.J., et al. (2015). Fenretinide prevents obesity in aged female mice in association 
with increased retinoid and estrogen signaling. Obesity (Silver Spring). 23: 1655–62.
Slawin, K., Kadmon, D., Park, S.H., Scardino, P.T., Anzano, M., Sporn, M.B., et al. 
(1993). Dietary fenretinide, a synthetic retinoid, decreases the tumor incidence and 
the tumor mass of ras+myc-induced carcinomas in the mouse prostate reconstitution 
model system. Cancer Res. 53: 4461–5.
Su, Z., Li, Y., James, J.C., Matsumoto, A.H., Helm, G.A., Lusis, A.J., et al. (2006). 
Genetic linkage of hyperglycemia, body weight and serum amyloid-P in an intercross 
between C57BL/6 and C3H apolipoprotein E-deficient mice. Hum. Mol. Genet. 15: 
1650–8.
Uner, A.G., Unsal, C., Unsal, H., Erdogan, M.A., Koc, E., Ekici, M., et al. (2018). 
Mice with diet-induced obesity demonstrate a relative prothrombotic factor profile 
and a thicker aorta with reduced ex-vivo function. Blood Coagul. Fibrinolysis 29: 
257–266.
Vik, R., Busnelli, M., Parolini, C., Bjørndal, B., Holm, S., Bohov, P., et al. (2013). An 
immunomodulating fatty acid analogue targeting mitochondria exerts anti-
atherosclerotic effect beyond plasma cholesterol-lowering activity in apoe(-/-) mice. 
PLoS One 8: e81963.
Page 32 of 57
British Pharmacological Society
British Journal of Pharmacology
For Peer Review
Wickham, H. (2007). Reshaping data with the reshape package. J. Stat. Softw. 21:.
Yvan-Charvet, L., Pagler, T., Gautier, E.L., Avagyan, S., Siry, R.L., Han, S., et al. 
(2010). ATP-binding cassette transporters and HDL suppress hematopoietic stem cell 
proliferation. Science 328: 1689–93.
Zizola, C.F., Frey, S.K., Jitngarmkusol, S., Kadereit, B., Yan, N., and Vogel, S. 
(2010). Cellular retinol-binding protein type I (CRBP-I) regulates adipogenesis. Mol. 
Cell. Biol. 30: 3412–20.
Page 33 of 57
British Pharmacological Society
British Journal of Pharmacology
For Peer Review
8. Figure and figure legends
Figure 1 – The weight of mice (n = 20 for EKO; n = 10 for BL/6) was monitored 2-3 
times a week for a period of 12 weeks total. (A) Average weight is plotted and shown 
within ±1 SD for either EKO (left) and BL/6 (right). Weight differences started to 
become steadily statistically significant starting from day 52 for EKO and day 61 for 
BL/6. Likewise, food and water intake were monitored per cage (mice were housed 3-
4 per cage) and normalized to the number of animals in each cage. Average values 
and SD are charted for each time point (B, D). For each time point, average intakes 
were normalized to the average weight of mice in each cage; the average of all 
measurements is charted for food (C, †: p = 0.0021, F-value 12.88) and water (E, ‡: p 
= 1.56×10-10, F-value 76.46; §: p = 6.8×10-6, F-value 39.00). Unpaired two-tailed 
Student’s T-test was used to test mean differences at each time point (A), significant 
differences are indicated by *. Repeated measures ANOVA was used to test for 
differences between groups throughout the entire duration of the study (B, D, 
graphically summarized in C, E respectively). Data are shown ± SD.
Figure 2 – After an i.p. injection of 2 g / Kg glucose (n = 16 randomly chosen EKO 
mice per group), glycaemia has been monitored at intervals of 25 minutes, up to 125 
minutes total. Glucose concentration as function of time is charted. *: p = 6.2×10-3; †: 
p = 3.6×10-2, ‡: p = 1.3×10-3 (A). Measurements of areas under the curve (AUC) are 
shown in B, in arbitrary units. Repeated measures ANOVA was used to test for 
statistically significant differences (A, p = 0.0651, F-score 3.66) and by unpaired two-
tailed Student’s T-test (B). Data are shown ± SD.
Figure 3 – Box plots of gene expression in the abdominal white adipose tissue (A) 
and liver (B) are shown (n = 12 randomly chosen EKO mice per group; each sample 
was run in triplicate). A: Fold changes of genes quantified in the abdominal white 
adipose tissue, relative to EKO-Ctrl group, are charted. *: p = 1.7×10-5; †: p = 3.4×10-
2; ‡: p = 3.2×10-4. B: Fold changes of hepatic genes, relative to EKO-Ctrl group, are 
charted. *: p = 6.6×10-4; †: p = 1.6×10-2; ‡: p = 2.4×10-7. Statistically significant 
differences were determined by unpaired two-tailed Student’s T-test. The upper and 
lower ends of the boxes indicate the 25th and 75th percentiles, respectively. The length 
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of the box shows the interquartile range within which 50% of the values are located. 
The solid gray lines denote the median.
Figure 4 – Total cholesterol (TC), triglyceride (TG) and phospholipid (PL) levels (n 
= 20, each sample was assayed in duplicate), quantified after 5 hours fasting, are 
shown. *: p = 8.0×10-5; †: p = 2.1×10-11, ‡: p = 4.2×10-2 (A). TC and TG distribution 
among plasma lipoproteins by FPLC is shown in B and C, respectively. Each profile 
was obtained from pooled plasma of all mice within each experimental group (n = 
20). Statistically significant differences were determined by unpaired two-tailed 
Student’s T-test. Data are shown ± SD.
Figure 5 – Representative image of aortas prepared with the en-face method (A). The 
aorta (n = 20 per group) was cut lengthwise and pinned flat onto a black wax surface, 
then the exposed plaques were quantified as a percentage of the whole aortic area; *: 
p = 3.0×10-7; †: p = 3.6×10-4; ‡: p = 2.6×10-9, §: p = 1.3×10-5 (B). Representative 
H&E photomicrographs of aortic sinuses (n = 20 per group, C). Plaque extent is 
reported as square micrometers p = 3.1×10-7 (D). Statistically significant differences 
were determined by unpaired two-tailed Student’s T-test. Data are expressed as mean 
± SD. Bar length= 500 μm.
Figure 6 – Cytologic evaluation of blood and bone marrow (n = 10 randomly chosen 
mice per group). RBC: red blood cells (erythrocyte number); WBC: white blood cells; 
HGB: haemoglobin; HCT: hematocrit; MCV: mean corpuscular volume; MCHC: 
mean corpuscular haemoglobin concentration; MCH: mean corpuscular haemoglobin; 
M/E ratio: monocyte to erythrocyte ratio. Statistically significant differences were 
determined by unpaired two-tailed Student’s T-test. Data are expressed as mean ± SD.
Figure 7 – Flow Cytofluorimetric evaluation of blood, spleen and bone marrow (n = 
5 randomly chosen mice per group). Total leukocyte count in the blood of EKO (A) 
and WT (D); count of T and B cells, monocytes and neutrophils in the blood of EKO 
(B) and WT (E); percentage of activated (Ly6Chi) and resting monocytes (Ly6Clo) in 
the blood of EKO (C) and WT (F). Total count of leukocytes in the femur of EKO 
and WT mice (G); percentage of myeloid precursors (CD11b+) on total leukocytes 
(H) and their subsets (J, L), representative dot plot from FACS analysis are shown (I); 
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Immature (Ly6Ghi) and mature (Ly6Glo) monocyte progenitors in EKO (K) and WT 
(M) bone marrow. Total count of spleen’s immune cells in EKO (N, P) and WT (O, 
Q); cell count corrected for spleen weight (mg) in EKO (R, T) and WT (S, U). GMP: 
granulocyte/monocyte progenitors; GP: granulocyte progenitors; MP: monocyte 
progenitors. Statistically significant differences were determined by unpaired two-
tailed Student’s T-test. *: p < 0.05; **: p < 0.01; ***: p < 0.001. Data are expressed as 
mean ± SD.
Figure 8 – Spleen (H&E, A,B); extramedullary hematopoiesis expanding the red pulp 
mostly represented by erythroid cells: mild in EKO-Ctrl (A) with a large follicle on 
the right and severe in EKO-Fen (B) with an atrophic follicle on the right.
Liver (H&E, C,D); extramedullary hematopoiesis: negative in EKO-Ctrl (C) and 
moderate in EKO-Fen expanding a portal area (D).
Liver (Perls’ iron stain, E,F); hemosiderin in the cytoplasm of Kupffer cells: negative 
in EKO-Ctrl (E) and mod rate, multifocal presence in EKO-Fen (F).
Kidney (H&E, G,H); hemosiderin, represented by granular brownish material, in the 
cytoplasm of proximal convoluted tubular epithelial cells: negative in EKO-Ctrl (G) 
and severe, multifocal presence in EKO-Fen (H).
Kidney (Perls’ iron stain, I,J); hemosiderin, represented by blue granules, in the 
cytoplasm of proximal convoluted tubular epithelial cells: negative in EKO-Ctrl (I) 
and severe, multifocal presence in EKO-fen (J). Bar length: 100 μm.
Figure 9: Flow cytometry analyses of percentage of (A) monocyte & neutrophil - 
platelet and (B) monocyte - platelet aggregates in whole blood of WT and EKO mice 
treated with or without fenretinide (n = 5 randomly chosen mice per group). In A, 
aggregates in EKO-Ctrl were higher than both untreated groups (p = 0.001 and p = 
7.96×10-5 vs WT and EKO, respectively), as well as aggregates in EKO-Fen were 
higher than both untreated groups (p = 0.004 and p = 2.5×10-4 vs WT and EKO, 
respectively). In B, aggregates in WT-Fen were different from all EKO conditions (p 
= 0.0128 and p = 1.3×10-5 vs EKO untreated and treated, respectively). Fenretinide 
treatment resulted in significantly different aggregates in EKO (p = 0.0017 in EKO-
Ctrl vs EKO-Fen). Statistically significant differences were determined by Kruskal-
Wallis one-way analysis of variance test, followed by Conover’s post-hoc test with 
Bonferroni p-value adjustment method. Top: the upper and lower ends of the boxes 
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indicate the 25th and 75th percentiles, respectively. The length of the box shows the 
interquartile range within which 50% of the values are located. The solid gray lines 
denote the median. Bottom: data are expressed as mean ± SD. 
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Supplementary	Figure	1	
Weight	of	organs	sampled	at	sacrifice	in	WT	(A)	and	EKO	(B)	mice	(EKO:	n	=	20;	WT:	n	=	10).	
*	 p	 =	 7.8×10-12;	 †	 p	 =	 2.8×10-8;	 ‡	 p	 =	 1.9×10-10;	 §	 p	 =	 0.035;	 ¶	 p	 =	 0.0056.	 Statistically	
significant	 differences	were	 determined	by	 unpaired	 two-tailed	 Student’s	 T-test.	Data	 are	
expressed	as	mean	±	SD.		
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Liver	histological	features	A	
C	
A:	In	the	liver	of	EKO	mice,	glycogen	accumulation	and	steatosis	were	given	an	arbitrary	score,	either	-	(absent),	+	(slight),	++	(moderate)	or	+++	(severe).	Their	distribution	
was	also	ranked	as	Diffuse	=	D;	Centrolobular	=	C;	Periportal	=	P;	Random	=	R.	B:	 representative	H&E	image	of	 liver	steatosis	 (arrows)	 in	EKO-Ctrl.	C:	 representative	H&E	
image	of	 hepatic	 glycogen	accumulation	 (arrows)	 in	 EKO-Ctrl.	D:	 representative	H&E	 image	of	 hepatic	 tissue	devoid	of	 steatosis	 and	 glycogen	accumulation	 in	 EKO-Fen.	
Features	were	evaluated	by	an	operator	blinded	to	experimental	groups.	Statistically	significant	differences	were	determined	by	unpaired	two-tailed	Mann-Whitney	U	test.	n	
=	10,	randomly	chosen.	Bar	length:	100	μm.	
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Supplementary	Figure	2	
Table	LIVER	-	Liver	histological	features	
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Supplementary	Figure	3	
Functional	 fibrinogen	 concentration	 in	 plasma	 is	 shown	 (n	 =	 5	 randomly	 chosen	 mice	 per	
group),	*	p=	0.0371.	Statistically	significant	differences	were	determined	by	Kruskal-Wallis	one-
way	 analysis	 of	 variance	 test,	 followed	 by	 Conover’s	 post-hoc	 test	 with	 Bonferroni	 p-value	
adjustment	method.	 Left:	 the	 upper	 and	 lower	 ends	 of	 the	 boxes	 indicate	 the	 25th	 and	 75th	
percentiles,	respectively.	The	length	of	the	box	shows	the	interquartile	range	within	which	50%	
of	the	values	are	located.	The	solid	gray	lines	denote	the	median.	Right:	data	are	expressed	as	
mean	±	SD.	
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Effect	of	fenretidine	treatment	on	WT	and	EKO	mice	on	the	percentage	of	total	leukocytes	-	platelets	(A)	and	neutrophil	-	
platelets	aggregates	(B)	(n	=	5	randomly	chosen	mice	per	group).	In	A,	aggregates	in	EKO-Ctrl	are	higher	than	WT-Ctrl,	WT-
Fen	and	EKO-Fen	 (*	 p	=	0.038,	0.032	and	0.0012	 respectively).	 In	B,	 there	were	 statistically	 significant	differences	only	
between	 genotype	 (†	 	 p	 =	 0.0159	 in	WT-Ctrl	 vs	 EKO-Ctrl;	‡	 p	 =	 0.0046	 in	 EKO-Ctrl	 vs	 EKO-Fen).	 Statistically	 significant	
differences	were	determined	by	Kruskal-Wallis	one-way	analysis	of	variance	test,	followed	by	Conover’s	post-hoc	test	with	
Bonferroni	 p-value	 adjustment	 method.	 Top:	 the	 upper	 and	 lower	 ends	 of	 the	 boxes	 indicate	 the	 25th	 and	 75th	
percentiles,	respectively.	The	length	of	the	box	shows	the	interquartile	range	within	which	50%	of	the	values	are	located.	
The	solid	gray	lines	denote	the	median.	Bottom:	data	are	expressed	as	mean	±	SD.	
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A.	In	the	lung,	inflammatory	infiltrates	were	evaluated	and	ranked	as	follows:	-	(no	infiltrate),	+	(rare,	<	3	infiltrates),	++	
(some,	 3	 -	 5	 infiltrates)	 and	+++	 (numerous,	 >	 5	 infiltrates).	 Cell	 types	 found	were	 labelled	 L	 (lymphocytes)	 and/or	 P	
(plasma	cells).	Foamy	macrophages	were	counted	per	field,	and	ranked	as	follows:	-	(absent),	+	(rare,	<	5),	++	(few,	5	-	
15),	+++	 (numerous,	>	15).	Cholesterol	crystals	were	similarly	 ranked	 from	none	 (-)	 to	abundant	 (+++).	Features	were	
evaluated	 by	 an	 operator	 blinded	 to	 experimental	 groups.	 Statistically	 significant	 differences	 were	 determined	 by	
unpaired	 two-tailed	Mann-Whitney	 U	 test.	 10	 random	 samples	 from	 EKO-Fen	 and	 EKO-Ctrl	 groups	 were	 chosen	 for	
analyses.	B,C:	representative	photomicrographs	of	H&E	stained	EKO-Ctrl	and	EKO-Fen,	respectively.	Bar	length:	100	μm.		
Supplementary	Figure	5	
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Supplementary	Figure	6	
Representative	H&E	photomicrographs	of	mouse	skin	sections.	A:	WT-Ctrl;	B	WT-Fen;	C	and	D:	EKO-Ctrl;	E	
and	F:	 EKO-Fen.	 Foam	 cells	 accumulation	 is	 shown	 in	 C,	 top-right	 and	 E,	 bottom-left.	 Cholesterol	 clefts	
accumulation	in	the	dermis	is	shown	in	E,	top-right.		
Bars:	A-F:	60	μm;	small	boxes:	15	μm.	
A
B	
C	
D	
E	
F	
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Gene	ID Forward	Primer	5'	→	3' Reverse	Primer	5'	→	3' Amplicon	size Organ(s)
Apob AGCGCCACCAAGATCAACTG GTTCGTACCTGGACATGGCA 178 liver
Cd36 GGTGGATGGTTTCCTAGCCTT GTGGCCCGGTTCTACTAATTCAT 135 liver
Cyp26a1 CCGTGAGAAGCTGCAGTGTA GGGTTCCATCCTTCAGCTCC 119 liver
Cyp7a1 AACAACCTGCCAGTACTAGATAGC GTGTAGAGTGAAGTCCTCCTTAGC 99 liver
Fasn GGAGGTGGTGATAGCCGGTAT TGGGTAATCCATAGAGCCCAG 140 liver
Hmgcr1 AGCCGAAGCAGCACATGAT GGGTATTGCTGGCCTCTTCA 215 liver
Ldlr TCGTAGTGGACCCTGTGCAT GGAAAGATCTAGTGTGATGCCATT 149 liver
Mttp AGCGTGGTGAAAGGGCTTAT CCACAGCCACCCGATTTTTC 178 liver
Scarb1 ATGGGCCAGCGTGCTTTTATGAAC ACGCCCGTGAAGACAGTGAAGACC 179 liver
Apoc3 CATCTGCCCGAGCTGAAGA GCTTGTTCCATGTAGCCCTGTAC 70 liver,	WAT
Lpl GGGAGTTTGGCTCCAGAGTTT TGTGTCTTCAGGGGTCCTTAG 115 liver,	WAT
Pck2 GGAGCACAAAGGAAAGACCA GACATGGAAGATACGAGGCAG 139 liver,	WAT
Ppia AGCACTGGGGAGAAAGGATT AGCCACTCAGTCTTGGCAGT 248 liver,	WAT
Lep AGCAGTGCCTATCCAGAAAGTCCA AATGAAGTCCAAGCCAGTGACCCT 127 WAT
Retn CCTACACACTCAGCAGTACGGAC TCAAACTCTGTATAGAACTTGCGGA 157 WAT
Slc2a4 CTGTGCCATCTTGATGACCGTG GTTGGAGAAACCAGCGACAGC 196 WAT
Cycling conditions were as follows: initial denaturation for 1' at 95 °C, followed by 40 cycles of 10s at 95°C and
30s at 60 °C. After the run, a melting curve was performed (0.5 °C increases over 5 seconds, from 65 °C to 95
°C).	Cqs	equal	or	higher	than	35	were	excluded	from	the	analysis	and	primer	pairs	calibration.
Supplementary	Table	1
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Hematopoiesis Follicular atrophy
Foamy 
macrophages
+ - -
++ - -
++ - -
+ - -
+ - +
+++ +++ -
+ - -
+ - -
+ - -
+ - -
+++ +++ +
+++ +++ -
+++ ++ -
++ ++ -
+++ ++ -
+++ ++ ++
++ + -
++ + -
+++ + -
++ + -
p=0.002 p=0.001 p=NS
Supplementary	Table	2	-	Spleen	histological	features
In the spleen, hematopoiesis and follicular atrophy features were evaluated and ranked as
follows: - (absent), + (slight), ++ (mild) and +++ (severe). Foamy macrophages were
counted per area, and ranked as follows: - (absent), + (rare), ++ (few), +++ (numerous).
Features were evaluated by an operator blinded to experimental groups. Statistically
significant differences were determined by unpaired two-tailed Mann-Whitney U test. 10
random	samples	from	EKO-Fen	and	EKO-Ctrl	groups	were	chosen	for	analyses.
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Glomerular lipidosis Tubular pigment deposition
++ -
++ -
+ -
+++ -
+++ -
++ -
++ -
+ -
+ -
++ -
+++ +++
++ ++
++ ++
++ +
+ +++
+ ++
+ +
- ++
++ +++
+ ++
p=NS p=2.8×10-5
EK
O
-C
tr
l
EK
O
-F
en
In the kidney, pigment deposition was evaluated and ranked as
follows: - (absent), + (slight), ++ (mild) and +++ (severe). Features
were evaluated by an operator blinded to experimental groups.
Statistically significant differences were determined by unpaired two-
tailed Mann-Whitney U test. 10 random samples from EKO-Fen and
EKO-Ctrl	groups	were	chosen	for	analyses.
Supplementary	Table	3	-	Kidney	histological	features
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Foam	cells Crystals Mast	cells Lymphocytes
- - + -
- - + -
- - + -
- - + -
- - + -
- - + -
- - + -
- - - -
- - + -
- - ++ -
p=NS p=NS p=NS p=NS
Foam	cells Crystals Mast	cells Lymphocytes
+ - ++ -
+ - - -
+++ + - -
++ - ++ -
+ - + -
+++ ++ - +
+++ +++ - +
+ - ++ -
- - + -
+ - + -
p=NS p=NS p=NS p=NS
p=0.000113 P=0.05054 p=NS p=NS
In the skin, foam cells, mast cells, lymphocytes and the presence of cholesterol crystals
were evaluated and ranked as follows: - (no infiltrate), + (rare), ++ (some) and +++
(numerous). Features were evaluated by an operator blinded to experimental groups.
Statistically significant differences were determined by unpaired two-tailed Mann-
Whitney U test. 5 random samples from WT-Ctrl, WT-Fen, EKO-Ctrl and EKO-Fen
groups	were	chosen	for	analyses.
WT	vs	EKO
Supplementary	Table	4	-	Skin	morphology
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Spleen
Ialine	cast
Lymphocytic	
interstitial	
infiltrate
Hypercellular	
glomeruli
Tubular	
Pigment	
Deposition
Glycogen Steatosis
Pigment	
deposition
Inflammatory	
infiltrate	
number
Infiltrate	size	
(S<10;	
M<100;	
L>100)
Inflammatory	
infiltrate	
number
Infiltrate	size	
(S<10;	
M<100;	
L>100)
Hematopoiesis single	cells group	of	cells
+ - - - ++ - - 2 M 0 - + - -
- ++ - - + - - 1 S 1 S + - -
- - - - ++ - - 1 S 1 S - - -
- - - - ++ - - 0 - 0 - - - -
+ - - - ++ - - 0 - 0 - + - -
+ - - - +++ - - 0 - 0 - + - -
- - - - + - - 3 S 0 - - - -
+ - - - ++ - - 3 S 1 S - - -
+ - - - + - - 3 S 1 S - - -
+ - - - +++ - - 0 - 0 - - - -
+ - - - + - - 1 S 0 - + - -
++ - - - + - - 2 S 0 - +++ - -
++ - - - + - - 1 M 0 - + - -
++ - - - + - - 3 S 0 - + - -
+ - - - + - - 1 S 1 M - - -
- - - - + - - 7 S 1 M - - -
- - - - ++ - - 1 M 0 - + - -
+ - - - ++ - - 4 S 0 - + - -
- - - - + - - 3 S 2 M + - -
- - + - + - - 0 - 0 - + - -
p	=	NS p	=	NS p	=	NS p	=	NS p	=	0.024 p	=	NS p	=	NS p	=	NS p	=	NS p	=	NS p	=	NS p	=	0.064 p	=	NS p	=	NS
W
T-
Ct
rl
W
T-
Fe
n
Histological features (n=10 per group) were scored as follows: Kidney: Ialine casts = ialine intratubular (medullary) cast: 1-3 = +; 4-10 = ++; < 10 = +++; Grading of other findings: - = absent; + =
slight; ++ = moderate; +++ = severe; Liver: grading of findings: - = absent; + = slight; ++ = moderate; +++ = severe; S = small (up to 10 cells); M = medium (11-100 cells); Spleen, Lungs: Grading of
findings: - = absent; + = slight; ++ = moderate; +++ = severe. For ranked data, statistically significant differences were determined by unpaired two-tailed Mann-Whitney U test. For numerical
data,	statistically	significant	differences	were	determined	by	unpaired	two-tailed	Student’s	T-test.
Supplementary	Table	5	-		Wild-type	histological	features
Kidney Liver Lungs
parenchymal perivasal Foamy	macrophages
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